Autolus Limited

6 trials 4 recruiting Commercial sponsor

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

4 Recruiting

1 Completed trials

2 Countries active

7 Unique IMPs

100% Results reported

Phase II

Phase I/II

Phase I (Other)

Phase II: 2 Phase I/II: 1 Phase I (Other): 3

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Systemic lupus erythematosus 2 Non-Hodgkin's lymphoma 1 Progressive multiple sclerosis 1

Top IMPs

AUTOLOGOUS ENRICHED T CELLS RETROVIRALLY TRANSDUCED TO EXPRESS TWO CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD22 4 FLUDARABINE PHOSPHATE 3 CYCLOPHOSPHAMIDE 2 AUTO4 1 CYCLOPHOSPHAMIDE MONOHYDRATE 1 PARACETAMOL 1 RITUXIMAB 1

All trials

6 total

A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY TO DETERMINE THE SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PARTICIPANTS WITH SEVE… Pending

2024-519941-32-00 Phase II 1 country AUTOLOGOUS ENRICHED T CELLS RETROVIRALLY TRANSDUCED TO EXPRESS TWO CHIMERIC ANTI…
A SINGLE-ARM, OPEN-LABEL, PHASE I STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF OBE-CEL IN PARTICIPANTS WITH REFR… Recruiting

2024-519552-93-00 Phase I (Other) 1 country
Long-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors. Recruiting

2024-511684-28-00 Phase II 1 country AUTO4; AUTOLOGOUS ENRICHED T CELLS RETROVIRALLY TRANSDUCED TO EXPRESS TWO CHIMER…
A Single-Arm, Open-Label, Phase 1 Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patient… Recruiting

2023-508236-60-00 Phase I (Other) 1 country
A Single-Arm, Open-Label, Multicenter, Phase 1b/2 Study Evaluating the Safety and Efficacy of AUTO1 (obecabtagene autoleucel [obe-cel]) in P… Recruiting

2023-506307-26-00 Phase I (Other) 1 country AUTOLOGOUS ENRICHED T CELLS RETROVIRALLY TRANSDUCED TO EXPRESS TWO CHIMERIC ANTI…
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult … Ended

2024-512903-38-00 Phase I/II 1 country AUTOLOGOUS ENRICHED T CELLS RETROVIRALLY TRANSDUCED TO EXPRESS TWO CHIMERIC ANTI…

Showing 1–6 of 6 trials

← All sponsors A–Z